Home Newsfeeds SVB Leerink Reiterates Outperform on Deciphera Pharmaceuticals, Maintains $30 Price Target

SVB Leerink Reiterates Outperform on Deciphera Pharmaceuticals, Maintains $30 Price Target

SVB Leerink analyst Andrew Berens reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and maintains $30 price target.

February 8, 2023

1 minute read

SVB Leerink analyst Andrew Berens reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and maintains $30 price target.

BlackRock’s Q1 Equity Fee Rates Were Light Across All Product Types, Analyst Cautions On Fee Rate Dynamics

April 12, 1:27 PM

Analyst flags concerns over BlackRock's Q1 equity fee rates, highlighting potential challenges amid revenue growth.

July 27, 1:23 PM

Arizona Regulator Recalls Tainted Products

February 13, 9:09 AM

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.

November 22, 9:50 AM

Morgan Stanley analyst Michael Phillips maintains Hartford Finl Servs Gr (NYSE:HIG) with a Equal-Weight and raises the price target from $76 to $80.